Search

Cookie policy

Introduction
When you visit the EHA website and/or EHA’s resource platform(s) (this includes all websites and pages, with the exemption of www. t2evolve.

Read more

EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms

Dates: October 12-14, 2017
Location: Budapest, Hungary
Chairs: C Harrison, JJ Kiladjian

EHA and the EHA Scientific Working Group on Myeloproliferative Neoplasms are organizing this EHA-SWG Scientific Meeting on Challenges in the Diagnosis and Management of Myeloproliferative Neoplasms.

Read more

New GFI1B variants in bleeding and platelet disorders

Platelets restrict blood loss upon vessel damage by formation of a clot (thrombus). Recently, we reported a family with a bleeding and platelet disorder (BPD), which was caused by a defect in the gene GFI1B1.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

Publications

Ruxolitinib for the management of myelofibrosis: Results of an international physician survey. Ellis MH, Koren-Michowitz M, Lavi N, Vannucchi AM, Mesa R, Harrison CN. Leuk Res. 2017 Oct;61:6-9. doi: 10. 1016/j. leukres. 2017. 08. 002.

Read more

‘Rare Cancers in all EU policies’: Prof Elizabeth Macintyre expresses strong EHA support for the Rare Cancers Europe agenda

On September 28, EHA President Elizabeth Macintyre addressed an audience that included Members of the European Parliament, and officials of the European Commission and the European Medicines Agency, as well as members of the Rare Cancers Europe (RCE) partnership.

Read more